{"id":"ce6237b2-e864-47ae-ba8a-db9a737cd1c7","question":"What are the pharmacokinetics of Emtricitabine in HIV-infected pediatric subjects aged 13 to 17 years?","reference_answer":"The pharmacokinetics of FTC at steady state were determined in 27 HIV-1-infected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg\/kg up to a maximum dose of 240 mg oral solution or a 200 mg capsule. Mean ± SD C and AUC were 2.7 ± 0.9 μg\/mL and 12.6 ± 5.4 μg∙hr\/mL, respectively.","reference_context":"Document 99: weighing >40 kg, receiving the 600 mg dose of EFV, C\n was 6.57 μg\/mL, C\n was\n2.82 μg\/mL, and AUC\n was 254.78 μM∙hr.\nEmtricitabine:\n \nThe pharmacokinetics of FTC at steady state were determined in 27 HIV-1-\ninfected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg\/kg up to\na maximum dose of 240 mg oral solution or a 200 mg capsule; 26 of 27 subjects in this\nage group received the 200 mg capsule. Mean ± SD C\n and AUC were 2.7 ± 0.9\nμg\/mL and 12.6 ± 5.4 μg∙hr\/mL, respectively. Exposures achieved in pediatric subjects\n12 to less than 18 years of age were similar to those achieved in adults receiving a once\nmax\nmax\nmax\nmax\nmax\nmin\n(0–24)\nmax","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":99,"topic":"Antiretroviral Therapy"}}
